Literature DB >> 9861234

Clinicopathological factors predicting retroperitoneal lymph node metastasis and survival in endometrial cancer.

X Tang1, K Tanemura, W Ye, K Ohmi, R Tsunematsu, T Yamada, N Katsumata, T Sonoda.   

Abstract

BACKGROUND: By clarifying the significance of clinicopathological factors for retroperitoneal lymph node metastasis and survival of patients with endometrial cancer, we suggest ideas for optimal treatment of this disease.
METHODS: A retrospective study was conducted in 310 women with endometrial cancer who underwent surgery with retroperitoneal lymphadenectomy. To evaluate retroperitoneal lymph node metastasis, age-adjusted and multivariable analyses were carried out for six clinicopathological factors including pathological grade, myometrial invasion, cervical invasion, peritoneal cytology, lymphatic permeation and vascular invasion. To evaluate survival, besides the above factors, a positive rate of metastasis of dissected retroperitoneal lymph nodes was included.
RESULTS: In 40 patients (13%) with nodal metastasis, the average positive rate of metastasis of dissected retroperitoneal lymph nodes was 22%. For retroperitoneal lymph node metastasis, the odds ratio of deep myometrial invasion, cervical invasion and severe lymphatic permeation were 5.97, 2.72 and 12.01, respectively. For survival, the hazard ratios of the positive rates of metastasis of dissected retroperitoneal lymph nodes (both 25% and < 25%), positive peritoneal cytology and poor pathological grade were 7.10, 3.24, 3.82 and 3.27, respectively, and 5-year survival rates for them were 0, 50, 72 and 77%, respectively.
CONCLUSIONS: For retroperitoneal lymph node metastasis, lymphatic permeation, deep myometrial invasion and cervical invasion were the independent prognostic factors. For survival, retroperitoneal lymph metastasis, poor pathological grades and positive peritoneal cytology were the independent prognostic factors. The positive rate of metastasis of dissected retroperitoneal lymph metastasis plays an important role in predicting survival of endometrial cancer. Lymph node biopsy is insufficient in treatment of this disease.

Entities:  

Mesh:

Year:  1998        PMID: 9861234     DOI: 10.1093/jjco/28.11.673

Source DB:  PubMed          Journal:  Jpn J Clin Oncol        ISSN: 0368-2811            Impact factor:   3.019


  6 in total

1.  Differential routes of carboplatin administration influence lymphocyte apoptosis in retroperitoneal lymph nodes.

Authors:  Yong-Wen Huang; Zheng Zeng; Su Li; Ji-Hong Liu
Journal:  Tumour Biol       Date:  2012-07-29

2.  The pattern of myometrial invasion as a predictor of lymph node metastasis or extrauterine disease in low-grade endometrial carcinoma.

Authors:  Elizabeth Euscher; Patricia Fox; Roland Bassett; Hayma Al-Ghawi; Rouba Ali-Fehmi; Denise Barbuto; Bojana Djordjevic; Elizabeth Frauenhoffer; Insun Kim; Sun Rang Hong; Delia Montiel; Elizabeth Moschiano; Andres Roma; Elvio Silva; Anais Malpica
Journal:  Am J Surg Pathol       Date:  2013-11       Impact factor: 6.394

3.  The effect of cell type on surgico-pathologic risk factors in endometrial cancer.

Authors:  Ahmet Taner Turan; Betül Dündar; Burcu Gündoğdu; Abdullah Boztosun; Nejat Ozgül; Nurettin Boran; Gökhan Tulunay; Ahmet Ozfuttu; Mehmet Faruk Köse
Journal:  J Turk Ger Gynecol Assoc       Date:  2011-03-01

4.  Prognostic discrimination of subgrouping node-positive endometrioid uterine cancer: location vs nodal extent.

Authors:  D S Kapp; T K Kiet; J K Chan
Journal:  Br J Cancer       Date:  2011-09-13       Impact factor: 7.640

5.  Association of Myometrial Invasion With Lymphovascular Space Invasion, Lymph Node Metastasis, Recurrence, and Overall Survival in Endometrial Cancer: A Meta-Analysis of 79 Studies With 68,870 Patients.

Authors:  Jianzhang Wang; Ping Xu; Xueying Yang; Qin Yu; Xinxin Xu; Gen Zou; Xinmei Zhang
Journal:  Front Oncol       Date:  2021-10-21       Impact factor: 6.244

6.  The impact of the absolute number and ratio of positive lymph nodes on survival of endometrioid uterine cancer patients.

Authors:  J K Chan; D S Kapp; M K Cheung; K Osann; J Y Shin; D Cohn; P L Seid
Journal:  Br J Cancer       Date:  2007-07-31       Impact factor: 7.640

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.